

Surgical Treatment for Ischaemic Heart Failure Trial (STICH)

| | | |
|--|---|---|
| Submission date 07/07/2010 | Recruitment status No longer recruiting | <input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol |
| Registration date 07/07/2010 | Overall study status Completed | <input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results |
| Last Edited 17/07/2014 | Condition category Circulatory System | <input type="checkbox"/> Individual participant data |

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Mr Mike Lammiman

Contact details
Department of Cardiology
Castle Road
Cottingham
United Kingdom
HU16 5JQ
mike.lammiman@hey.nhs.uk

Additional identifiers

ClinicalTrials.gov (NCT)
NCT00023595

Protocol serial number
5148

Study information

Scientific Title

Surgical Treatment for Ischaemic Heart Failure Trial (STICH): a multicentre randomised interventional treatment trial

Study objectives

No randomised trial has ever directly compared long-term benefits of surgical and medical treatment of patients with ischaemic heart failure (HF). Along the broad spectrum of severity of ischaemic HF, specific clinical information, such as severe angina or left main coronary artery stenosis, may clearly indicate the need for surgical therapy for some patients.

However, a large number of patients fall into a gray zone without clear evidence for benefit from either medical or surgical therapy. For these patients, evidence supporting choice between therapies was never strong and has only been confused by recent studies showing improved outcomes with both therapies.

Patients for whom equipoise of anticipated benefit now exists between modern medical and surgical therapy represent the broad population who are appropriate candidates for a randomised trial to provide the context for assessing the value of two therapeutic strategies:

1. Medication (MED) alone
2. MED and coronary artery bypass grafting (CABG)

The study is also being run in the USA and includes surgical ventricular reconstruction as a treatment option in those sites only.

As of 13/07/2010 the study is seeking a protocol amendment to extend follow-up for another 9 years.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Hull and East Riding REC, 04/08/2005, ref: 05/MRE00/51

Study design

Multicentre randomised interventional treatment trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Topic: Cardiovascular; Subtopic: Cardiovascular (all Subtopics); Disease: Cardiovascular

Interventions

1. Optimal medication (for heart failure according to National Institute for Clinical Excellence [NICE] guidelines)
2. CABG and optimal medication

Total duration of treatment: up to 6 years maximum

Follow-up length: 36 months

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

CABG combined with MED compared to MED alone, measured up to 6 years.

Key secondary outcome(s)

Measured up to 6 years:

1. Cardiac magnetic resonance (CMR) of left ventricle (LV) shape, size and function for predicting the benefit of a specific treatment strategy
2. Nuclear cardiology and/or echocardiography testing of myocardial ischaemia

Completion date

30/05/2007

Eligibility

Key inclusion criteria

1. Men
2. Women who are not of childbearing potential
3. Aged 18 years or above
4. Who have a left ventricular ejection fraction (LVEF) less than 0.35 measured by cardiac magnetic resonance (CMR) ventriculogram, gated single photon emission computed tomography (SPECT) ventriculogram, echocardiography, or contrast ventriculogram within three months of trial entry
5. Who have coronary artery disease suitable for revascularisation

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Failure to provide informed consent
2. Aortic valvular heart disease clearly indicating the need for aortic valve repair or replacement
3. Cardiogenic shock (within 72 hours of randomization) as defined by the need for intra-aortic balloon support or the requirement for intravenous inotropic support
4. Plan for percutaneous intervention of coronary artery disease
5. Recent acute myocardial infarction judged to be an important cause of left ventricular dysfunction
6. History of more than one prior coronary bypass operation
7. Non-cardiac illness with a life expectancy of less than 3 years
8. Non-cardiac illness imposing substantial operative mortality
9. Conditions/circumstances likely to lead to poor treatment adherence (e.g., history of poor compliance, alcohol or drug dependency, psychiatric illness, no fixed abode)
10. Previous heart, kidney, liver, or lung transplantation
11. Current participation in another clinical trial in which a patient is taking an investigational drug or receiving an investigational medical device

MED Therapy Eligibility Criteria:

12. Absence of left main coronary artery disease as defined by an intraluminal stenosis of 50% or greater
13. Absence of Canadian Class III angina or greater (angina markedly limiting ordinary activity)

Date of first enrolment

22/12/2005

Date of final enrolment

30/05/2007

Locations

Countries of recruitment

United Kingdom

England

United States of America

Study participating centre

Department of Cardiology

Cottingham

United Kingdom

HU16 5JQ

Sponsor information

Organisation

Duke University (USA)

ROR

<https://ror.org/00py81415>

Funder(s)

Funder type

Government

Funder Name

National Institute for Health Research (NIHR) (UK)

Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Funder Name

National Institutes of Health (NIH) (USA) - National Heart, Blood and Lung Institute (ref: 5 U01 HL069015-4)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---------------------------------|---------|--------------|------------|----------------|-----------------|
| Results article | results | 23/04/2009 | | Yes | No |
| Results article | results | 01/05/2009 | | Yes | No |
| | results | | | | |

| | | | | | |
|---|-------------------------------|------------|------------|-----|-----|
| Results article | | 03/08/2010 | | Yes | No |
| Results article | results | 03/08/2010 | | Yes | No |
| Results article | results | 28/04/2011 | | Yes | No |
| Results article | results | 28/04/2011 | | Yes | No |
| Results article | results | 01/03/2012 | | Yes | No |
| Results article | results | 29/05/2012 | | Yes | No |
| Results article | results | 01/01/2013 | | Yes | No |
| Results article | results | 01/05/2013 | | Yes | No |
| Results article | results | 07/05/2013 | | Yes | No |
| Results article | results | 01/10/2013 | | Yes | No |
| Results article | results | 01/10/2013 | | Yes | No |
| Results article | results | 01/11/2013 | | Yes | No |
| Results article | results | 01/12/2013 | | Yes | No |
| Results article | results | 01/08/2014 | | Yes | No |
| Protocol article | protocol | 01/12/2007 | | Yes | No |
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
| Study website | Study website | 11/11/2025 | 11/11/2025 | No | Yes |